Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Home · Providers · Mochi Health
Provider Review · 73/100 · Updated 2026-06-19

Mochi Health Review

NP-led compounded semaglutide model. Two pillars met (clinical protocol, follow-up cadence). Pricing is competitive in the compounded segment.

#9 of 1073/100$209/mo
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-19

Overview

NP-led compounded semaglutide model. Two pillars met (clinical protocol, follow-up cadence). Pricing is competitive in the compounded segment.

Mochi Health at a glance

Editorial rank
#9 of 10
Score
73/100 · 3.6/5 stars
Pillars met
2 of 6
Pricing
$209/mo
Pharmacy model
503A compounded
Clinical model
Compounded, NP-led
Website
joinmochi.com

Six-pillar scoring

Mochi Health meets 2 of 6 v3.0 transparency pillars. Two pillars met indicates a stronger profile but still gaps versus the rubric leaders.

Pricing

$209/mo. Verify final pricing directly with the provider before purchasing — prices may change.

Trade-offs to know

How to evaluate Mochi Health

If you're considering Mochi Health, verify directly: (1) named Medical Director and state licensure, (2) the dispensing pharmacy on every shipment label, (3) whether per-batch CoAs (USP <71>, USP <85>, HPLC potency) are available on request, (4) the full out-of-pocket monthly cost across the titration schedule, (5) the FDA-approval status of any medication you're prescribed.

Visit Mochi Health →

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence pointPublished dataWhat it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 statusFDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.Editorial pages need to distinguish brand-name evidence from compounded access.
State accessTelehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing